Drug evaluation: LB-80380--a novel phosphonate nucleoside for the potential treatment of HBV infection

Curr Opin Mol Ther. 2006 Aug;8(4):352-7.

Abstract

LG Life Sciences Ltd (formerly LG Chem Ltd), in collaboration with Anadys Pharmaceuticals Inc, is developing LB-80380 (PMCDG dipivoxil), an orally available lead compound in a series of phosphonate nucleotides, for the potential treatment of hepatitis B virus infection. In April 2003, phase II trials were initiated, the results of which were reported in February 2006. LB-80380 is the prodrug of LB-80317 (PMCDG), another compound from this series.

Publication types

  • Review

MeSH terms

  • Animals
  • Antiviral Agents / chemistry
  • Antiviral Agents / pharmacokinetics
  • Antiviral Agents / therapeutic use*
  • Clinical Trials as Topic
  • Guanine / analogs & derivatives*
  • Guanine / chemistry
  • Guanine / pharmacokinetics
  • Guanine / therapeutic use
  • Hepatitis B / drug therapy*
  • Humans
  • Organophosphonates / chemistry
  • Organophosphonates / pharmacokinetics
  • Organophosphonates / therapeutic use*

Substances

  • ((1-((2-amino-9H-purin-9-yl)methyl)cyclopropyl)oxy)methylphosphonic acid dipivoxyl
  • Antiviral Agents
  • Organophosphonates
  • Guanine